Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Exp Neurol. 2014 Feb 6;254:180–189. doi: 10.1016/j.expneurol.2014.01.020

Figure 3.

Figure 3

SN79 mitigates METH-induced increases in striatal GFAP immunoreactivity. METH (5 mg/kg x 4) resulted in significant increases in GFAP immunofluorescence. This effect was blocked by SN79 (3 mg/kg × 4) treatment. (A) Qualitative images of GFAP immunoreactivity in response to METH and blockade by SN79 treatment. Clockwise from top left: Sal/Sal, Sal/METH, SN79/METH, SN79/Sal. Large images = 20×; Inset images = 63×. (B) Quantification of the attenuation of METH-induced increases in GFAP immunoreactivity by SN79 treatment. One-way ANOVA, followed by post hoc Tukey's multiple comparison tests. n=5/group, 3 slices/brain averaged for each data point. **p < 0.01, Sal/METH vs. Sal/Sal; ##p < 0.01, SN79/METH vs. Sal/METH